【U.S. Stock Market Movement】Snap surges on October 9: External Specs financing and advertising growth
Bitget异动解读2026/10/09 15:05Interpretation of Snap's Surge on October 9
Keywords: External Financing for Specs, Advertising Growth
1. On October 6, shareholder Blue Duck Capital suggested that Snap introduce external capital for Specs, believing that this could reduce Specs development expenses for core business by approximately $500 million annually and establish a market valuation of around $5 billion for Specs.
2. On October 5, Collabstr launched a Snap marketing collaboration channel for creators on Snapchat, where over 25% of the platform’s more than 1 million creators are able to participate in Snap's marketing campaigns; Snapchat’s daily active users number 493 million, providing a user base for the expansion of its advertising business.
3. As of June 30, Snap's second-quarter revenue was $1.599 billion, a 19% year-on-year increase, with average revenue per user at $3.25; the company’s main method of commercialization is through advertising.
(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cross-chain atomic transactions between Ethereum mainnet and L2
US Stock Movement | US clinical-stage biopharmaceutical company Retension Pharmaceuticals (RTSN.US) enters the US stock market, shares drop over 10% after opening
According to Jinse Finance, Retension Pharmaceuticals (RTSN.US) debuted on the US stock market on Friday and fell over 10% to $10.77 at press time, with an IPO price of $12. Retension Pharmaceuticals is a US-based clinical-stage biopharmaceutical company focused on developing innovative drugs for the treatment of hypertension and other cardiovascular diseases. The company's core investigational drug, RTN-001, is a new generation phosphodiesterase 5 (PDE5) inhibitor, primarily targeting patients with uncontrolled or resistant hypertension, and is currently undergoing a Phase IIb clinical trial. This drug works by enhancing nitric oxide signaling in blood vessels to promote vasodilation and lower blood pressure. The exclusive global development license comes from French pharmaceutical giant Sanofi (SNY.US).
Chevron has suspended production operations at five facilities in the U.S. Gulf region.
Chevron (CVX.US) has evacuated personnel and shut down production operations at five facilities in the US Gulf region, while another four offshore platforms continue production.
Crypto prices
More
